Infusion of donor-derived hematopoietic stem cells in organ transplantation: clinical data.
Many strategies for tolerance induction have been developed, because this is the major goal of clinical transplantation. One of the most effective and best-studied approaches has been based on the injection of hematopoietic cells derived from the donor bone marrow, to establish a state of microchimerism in the recipient. A subset of hematopoietic stem cells might be responsible for the tolerogenic properties. These CD34+ bone marrow stem cells can be isolated and safely injected into kidney transplant recipients. In the authors' clinical trial, no adverse effects were observed, and the infusion of donor CD34+ cells was well tolerated.
De Pauw
Luc
L
Nephrology Department, Hôpital Erasme, Brussels, Belgium. ludepauw@ulb.ac.be
Toungouz
Michel
M
Goldman
Michel
M
D018952:Antigens, CD34 / Q000378:metabolism; D001854:Bone Marrow Cells / Q000378:metabolism; D016026:Bone Marrow Transplantation; D002102:Cadaver; D006084:Graft Rejection / Q000453:epidemiology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015994:Incidence; D016030:Kidney Transplantation; D014019:Tissue Donors; D018183:Transplantation Chimera; D019172:Transplantation Conditioning / Q000379:methods; D023001:Transplantation Tolerance
D018952:Antigens, CD34